Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ellen Colgan

Podiatrist Warrenton, MO Doctor of Podiatric Medicine

NPI 1013304948 CMS profile 2790425

18800 Schnucks Dr, Warrenton, MO 63383

Open in the dashboard

General payments

$9,842

205 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ellen Colgan of Warrenton, MO is reported in the CMS Open Payments database as having received $9,842 across 205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $607 10
2024 General $813 10
2023 General $3,521 89
2022 General $2,298 20
2021 General $1,364 33
2020 General $581 20
2019 General $658 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ellen Colgan
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Ellen Colgan were reported at $607. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Ellen Colgan Podiatrist median Middle half National median
2019 $658 $196 $72–$601 $163
2020 $581 $118 $38–$335 $114
2021 $1,364 $169 $57–$573 $132
2022 $2,298 $220 $74–$782 $149
2023 $3,521 $208 $71–$635 $160
2024 $813 $237 $87–$681 $164
2025 $607 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,341 22 payments
  2. Treace Medical Concepts, Inc. $2,257 19 payments
  3. Elite Orthopedics, LLC $1,810 13 payments
  4. Organogenesis Inc. $991 62 payments
  5. Integra LifeSciences Corporation $750 23 payments
  6. Smith+Nephew, Inc. $385 23 payments
  7. Kerecis Limited $306 4 payments
  8. Abbott Laboratories $181 2 payments
  9. Kowa Pharmaceuticals America, Inc. $169 16 payments
  10. Tactile Systems Technology Inc $121 3 payments
  11. Other $532 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,238 201 payments
  2. Travel and Lodging $1,404 3 payments
  3. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM $2,062 15 payments
  2. AUGMENT INJECTABLE $910 7 payments
  3. Puraply $737 56 payments
  4. PRIMATRIX $505 15 payments
  5. INTEGRA DERMAL REGENERATION TEMPLATE $505 15 payments
  6. VARIAX $408 4 payments
  7. Integra Recon-Skin And Wound $393 13 payments
  8. Integra Recon-Skin And Wound $393 13 payments
  9. Integra Recon-Skin And Wound $393 13 payments
  10. EASYFUSE $294 2 payments
  11. Other $6,138 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

289

Median for Podiatry: 160

Drug cost

$3,814

Median for Podiatry: $2,368

Branded share of claims

24.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 60 $1,340
Pregabalin Generic 24 $842
Ciclopirox Generic 23 $462
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $259
Gentamicin Sulfate Generic 15 $205
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $156
Methylprednisolone Generic 20 $145
Mupirocin Generic 29 $119
Cefadroxil Generic 17 $113
Allopurinol Generic 18 $90

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$27,426

Of which drugs: $1,998

Medicare patients

193

Average age 74

Services billed

610

111 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 38%
Chronic kidney disease 31%
Ischemic heart disease 26%
Heart failure 22%
Depression 21%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 30 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record